Blog

Goldman Sachs, Morgan Stanley and J.P. Morgan are broadly aligned on 2026 as an AI driven but more selective year for healthcare and technology, with higher capital deployment, more focused M&amp;A &nbsp;and a premium on profitable, workflow‑integrated healthtech.​Shared big picture for 2026 All three see AI as a core productivity and earnings driver across sectors, with healthcare one of the main beneficiaries of full‑scale adoption and associated capex.​ The macro backdrop is framed as slower but positive growth with lower rates and more dispersion, favouring quality growth and cash‑generative platforms in healthcare and tech over speculative stories.​ Healthcare and healthtech views Goldman flags healthcare as a prime beneficiary of an innovation‑driven M&amp;A cycle into 2026, with larger, platform‑style deals in AI‑enabled revenue cycle, workflow platforms, advanced diagnostics and clinically validated digital therapeutics.​ J.P. Morgan’s healthcare technology spotlight expects AI‑enabled healthtech (ambient documentation, analytics, automation) to become the norm, with AI features commanding valuation premia as adoption rises among providers and payors.​ MedTech and services angles Morgan Stanley explicitly calls out a 2026 “healthcare revival,” overweight the sector, and is bullish on MedTech as post‑pandemic inventory and supply chain issues clear, enabling more normalised growth and renewed capital deployment.​ Across the banks, structural themes include shift to lower‑acuity and home‑based care, at‑home diagnostics and monitoring, and “plug‑and‑play” hospitals where robotics and devices integrate into modular clinical spaces.​ AI, capex and digital infrastructure Goldman expects AI capex by hyperscalers and large platforms to exceed 500 billion dollars by 2026, with an expanding universe of beneficiaries beyond core infrastructure into application‑layer and productivity tools, including healthcare IT.​ J.P. Morgan and Morgan Stanley both emphasise AI moving from experimentation to production, with use cases like imaging, predictive monitoring, scheduling and documentation driving measurable efficiency and clinical impact.​ Capital markets and M&amp;A setup Goldman’s global M&amp;A outlook and healthcare‑specific synthesis point to higher healthcare deal volumes, more transformative transactions and strategics/PE using M&amp;A to acquire AI and data capabilities rather than build them in‑house.​ Morgan Stanley highlights a K‑shaped recovery where high‑ROIC, innovation‑rich assets command premiums and MedTech uses divestitures plus focused M&amp;A in cardiovascular, neuro and other high‑growth segments to re‑rate.

Goldman Sachs, Morgan Stanley and JP Morgan’s combined Healthcare and Technology predictions for 2026

The prevailing mood at the 2026 J.P. Morgan Healthcare Conference is cautious but clearly more constructive, with renewed focus on execution, capital discipline, and selective growth/M&amp;A rather than a broad-based risk‑on rebound.​Overall tone For biotech, sentiment is described as cautious yet more positive than 2025, with capital available but highly selective and discipline around valuations and proof points.​ Across the week, investors are shifting from story-driven narratives to underwriting execution, governance, and credibility, signalling a return to capital discipline rather than momentum chasing.​ Capital, IPOs and M&amp;A Multiple JPM recaps frame 2026 as a potential comeback year for deal-making, with rebuilding M&amp;A momentum and expectations of more strategic acquisitions and roll‑ups, especially around AI and tech‑enabled services.​ The new issue window is seen as thin but open for a handful of scaled, profitable or clearly de‑risked issuers, while take‑privates and sponsor‑led deals remain an important release valve.​ Thematic “mood music” AI has moved from hype to accountability: conversations emphasise real‑world ROI, integration into core infrastructure (R&amp;D, diagnostics, rev cycle, ops) and governance, rather than generic “AI for everything” pitches.​ Policy, regulation and trust (especially around AI/ML, data, and reimbursement) are being treated as first‑order business variables, not sidebars, adding a sober, compliance‑aware tone to the optimism.​ Corporate messaging and fundamentals Mega‑ and large‑cap pharma/medtech are striking an upbeat note on medium‑term growth and launch pipelines, stressing “focus on fundamentals” and durable mid‑single‑digit to high‑single‑digit growth targets.​ Across management teams, there is more emphasis on profitability, unit economics, and operational leverage in digital health and tech‑enabled models, and less appetite for loss‑making growth stories without a credible path to cash generation.​ How it feels on the ground Commentators describe JPM 2026 as a barometer showing AI and data as mainstream, M&amp;A momentum rebuilding, and investors rewarding proven business models over blue‑sky narratives.​ A recurring takeaway is that reputation, trust, and transparency around AI and clinical value have become strategic assets, which is tempering exuberance and pushing the tone toward measured, fundamentals‑driven optimism.

What is the mood music at JP Morgan Healthcare conference 2026 this week?

The commencement of 2026 has heralded a definitive paradigmatic shift in the trajectory of consumer health technology, characterised principally by the transition from passive information retrieval to active, agentic health management. At the vanguard of this transformation is OpenAI’s aggressive expansion into the healthcare vertical, a strategy crystallised by two simultaneous, high-impact manoeuvres : the acquisition of the specialised healthcare technology startup Torch Health and the launch of the dedicated ChatGPT Health environment. On January 12, 2026, OpenAI confirmed the acquisition of Torch Health in an all-equity transaction valued between $60 Million and $100 Million. This strategic consolidation represents more than a mere talent acquisition; it signals the integration of critical infrastructure designed to solve the "context problem" in medical artificial intelligence. For nearly a decade, the promise of AI in healthcare has been stymied by the fragmentation of patient data, longitudinal records scattered across disparate electronic health record (EHR) systems, pdf lab reports, and siloed wearable metrics. The industry's inability to synthesise this fragmented data into a coherent "medical memory" has prevented Large Language Models (LLMs) from moving beyond generic medical advice to personalised health surveillance. &nbsp;&nbsp; Simultaneously, the deployment of ChatGPT Health, a privacy-segregated ecosystem within OpenAI's flagship platform, and OpenAI for Healthcare, a HIPAA-compliant enterprise suite, marks the operationalisation of this new capability. By integrating Torch’s "context engine," OpenAI aims to transition its 40 million daily health-seeking users from receiving static answers to engaging with a "personal super-assistant" capable of longitudinal reasoning. &nbsp;&nbsp; This report provides an analysis of this pivotal moment in health technology. It scrutinises the architectural necessity of Torch’s "medical memory," dissects the complex failure of the Forward Health model that spawned the Torch team and evaluates the intensifying competitive landscape involving Anthropic and legacy health IT incumbents.&nbsp; Full Report: <a href="https://www.healthcare.digital/single-post/openai-s-acquisition-of-torch-health-and-the-future-of-chatgpt-health">https://www.healthcare.digital/single-post/openai-s-acquisition-of-torch-health-and-the-future-of-chatgpt-health</a>Furthermore, it examines the privacy paradox introduced by the consumerisation of sensitive medical records outside the protective umbrella of HIPAA, forecasting the clinical and ethical ripple effects of this technological convergence.

The Future of ChatGPT Health

Anthropic has just launched Claude for Healthcare, a HIPAA‑ready offering aimed at providers, payers, life sciences, and consumer health applications, with a focus on safety, interoperability, and complex workflow automation. For an M&amp;A / build‑vs‑partner view, it effectively positions Claude as an “agentic copilot” across admin ops, clinical documentation, and life‑sciences workflows, and is already embedded in several scaled health players.​What Claude for Healthcare is Anthropic now offers a dedicated Claude for Healthcare stack, including configuration and resources so providers, payers, and health apps can use Claude through HIPAA‑ready products.​ The launch coincides with expanded life‑sciences tooling (e.g., connectors into scientific platforms, trial ops, regulatory workflows) under the broader Claude for Life Sciences umbrella.​ Core healthcare use cases Provider / health system side​Prior authorisation and claims: Drafting and packaging prior auth requests and appeals by pulling from records, coverage policies, and guidelines. Patient communication and triage: Sorting portal messages, flagging urgent issues, and drafting responses or routing tasks to the right team. Clinical documentation: Used by partners like Commure for ambient scribing and documentation, targeting “millions of clinician hours” saved annually.​ Payer and revenue‑cycle side​Claims appeals and utilization review: Assembling evidence from EMR, guidelines, and policies to support denials/appeals. Member communication: Explaining coverage decisions and benefits in plain language and assisting with care navigation. Life sciences and pharma applications Claude is being used by large pharma and biotech (e.g., Sanofi, AstraZeneca, Genmab) for literature review, protocol drafting, regulatory document prep, and analytics.​ Example: A Phase II Parkinson’s trial protocol was generated in about an hour instead of days, using Claude to structure and iterate on the design.​ With integrations like Benchling, Claude can draft SOPs, study protocols, consent forms, and support GxP‑compliant documentation and submissions.​ Patient‑facing and data interoperability angle A new consumer‑health push lets patients link their electronic health records (EHRs) via partners like HealthEx, then ask Claude questions about their own data (history summaries, test result explanations, pattern detection across devices, etc.).​ Anthropic has joined the U.S. CMS “Health Tech Ecosystem” pledge, positioning Claude as an interoperability layer to break data silos and support AI assistants that can navigate health data across systems.​ Technical performance and safety positioning Claude’s latest flagship (Opus 4.x) is benchmarked as strong on clinical knowledge, with reported performance at around 95% on the 2025 MRCGP exam, above mean human GP scores, underscoring its viability for complex clinical reasoning support (though not as an autonomous clinician).​ Anthropic is explicitly marketing safety as a differentiator in regulated environments, emphasising constrained use, auditable outputs, and alignment work to reduce harmful or hallucinated clinical guidance.<a href="https://claude.com/solutions/healthcare">https://claude.com/solutions/healthcare</a>

Anthropic launches Claude for Healthcare

Distressed M&amp;A is forecast to be a structural, not cyclical, feature of European HealthTech and MedTech dealmaking in 2026, driven by a convergence of regulatory capital requirements, funding market resets and operational pressures that create a clearing event for undercapitalised assets.​To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener" data-mce-selected="inline-boundary">lloyd@nelsonadvisors.co.uk</a>Core drivers of distressed activityRegulatory Darwinism is the primary catalyst. Full MDR/IVDR implementation, EUDAMED mandatory go‑live (May 2026), and AI Act compliance have created capital‑intensive barriers that act as a “guillotine” for stand‑alone SMEs. Notified Body certification, clinical data generation, post‑market surveillance and data governance requirements are largely untenable for companies without deep balance sheets, forcing them into the arms of larger strategics that possess scaled regulatory infrastructure. This is explicitly framed as “compliance‑driven M&amp;A,” where acquirers target IP, customer bases and regulatory approvals from firms that cannot afford the transition costs.​Private equity liquidity pressures compound the dynamic. With ~$2.5 trillion in global dry powder and a significant backlog of 2019–2021 vintage assets requiring exit, PE sponsors face immense pressure to return capital to LPs. However, the IPO market remains selective, focusing only on assets with proven profitability and scale. Consequently, sponsors are increasingly utilising continuation funds, secondary buyouts and forced sales to drive consolidation, with 38% of European M&amp;A respondents expecting distress‑driven deals to dominate buy‑side activity. Financing difficulties and valuation gaps are cited as key deal drivers, creating a pool of forced sellers.​Operational and market stress is accelerating in specific sub‑sectors. Companies that achieved product‑market fit but failed to secure reimbursement traction or scale revenue are now facing flat or shrinking growth, making them prime targets for IP‑only or acqui‑hire transactions at compressed valuations. The combination of elevated cost of capital, investor retrenchment and regulatory overhead is creating a “funding reset” that will flush out “zombie” assets through down rounds, recapitalisations and pay‑to‑play restructurings.​Most vulnerable sub‑sectorsMedTech devices and diagnostics face the clearest distress risk. MDR/IVDR transition costs, UKCA divergence and rising quality‑system expenses (QMSR alignment, EUDAMED, sustainability rules) are squeezing smaller UK and EU manufacturers, many of which are expected to sell under pressure. Generalist CDMOs are also vulnerable, though specialists in viral vectors, ADCs and sterile injectables remain attractive.​Digital health and HealthTech platforms that built inflated cap tables during 2021–22 but lack clear reimbursement or sustainable unit economics are prime distressed targets. Investors are prioritising companies with robust clinical validation and AI integration; those without face acquisition for IP rather than revenue. Early‑stage AI companies that “moved fast and broke things” without regulatory foundations are becoming uninvestable and will exit as distressed sales.​Veterinary, dental and ophthalmology services in the UK are experiencing a “corporatisation clash” and “locum crisis,” with regulatory scrutiny (the “CMA Effect”) pushing capital toward Continental Europe where corporate ownership is lower (15–20% vs. ~60% in the UK). This is creating distressed sellers in the UK and fragmented buy‑and‑build opportunities in Southern Europe.​Buyer strategies and opportunities Strategic acquirers (Roche, Siemens Healthineers, Abbott, Medtronic, J&amp;J, Philips) are using M&amp;A to secure “compliance moats” and data sovereignty. They are targeting AI‑native platforms, robotics and digital pathology assets that can be integrated across existing portfolios, with a focus on H1 2026 to get ahead of EHDS implementation.​Private equity is deploying buy‑and‑build strategies in fragmented services (veterinary, dental, fertility) across Southern and Eastern Europe, acquiring at low multiples (6x–8x EBITDA) and integrating into pan‑European platforms that command premium exits (12x–15x EBITDA). PE is also forming club deals with corporate buyers in high‑growth verticals like mental health tech, femtech and preventive care.​US corporate venture funds are increasingly active in Europe, seeking early exposure to robotics and AI innovation before valuations reach US levels, effectively bridging the “Series B Gap” for European companies.​Deal structure and valuation implications Distressed transactions are expected to feature:Compressed valuations relative to 2021–22 peaks, with multiples stabilising around ~4.8x revenue and low‑teens EV/EBITDA by Q4 2025.​ IP‑only or acqui‑hire structures for digital health assets lacking revenue scale.​ Regulatory due diligence as a core financial assessment, with compliance profiles treated as assets or liabilities.​ Continuation funds and secondary buyouts to manage PE portfolio churn.​ Outlook 2026 is described as the year European HealthTech “grows up,” graduating from the “laboratory” phase to the “factory” phase. The winners will not be those with the most disruptive technology, but those with the strongest compliance moats, interoperable data and industrial logic. Distressed M&amp;A is the primary mechanism clearing the market of subscale, over‑funded or non‑compliant assets, making it a central pillar of European HealthTech and MedTech consolidation rather than a peripheral trend.To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener">lloyd@nelsonadvisors.co.uk</a>

Distressed M&A predicted to play a major role in European HealthTech and MedTech 2026

European HealthTech this week is dominated by EU‑level AI and data policy moving into implementation, new EU and national funding windows for digital health, and early‑year signals of tighter but more predictable MedTech regulation in 2026. Dealmaking and startup activity continue to tilt towards AI‑enabled automation, data‑rich diagnostics and devices, and cross‑border virtual care infrastructure.​Policy and regulatory moves The European Commission has released a new report on emerging health technologies, feeding into implementation of the AI Act, MDR/IVDR and broader digital health strategy as the reference framework for “robust and trustworthy” AI in care.​ EU commentary now explicitly links the AI Act, MDR and the Digital Omnibus as the core stack for health AI, aiming to harmonise rules and cut compliance friction for innovators from 2026 onward.​ NHS England is preparing for 2026 workforce and digital policy changes, with an overhaul of workforce models tied to expanded use of digital tools and automation across the system.Funding windows and capital flowsThe UNITE Open Call for European digital health innovators is live with a €4 million budget, offering up to €1 million per cross‑border project and a submission deadline of 15 January 2026.​The 2026 cycle of the Future of Health Grant in Switzerland is opening this month, targeting early‑stage digital health startups in telemedicine, patient analytics, preventive care and digital therapeutics.​ Horizon Europe’s 2026–2027 work programme allocates part of a €14 billion R&amp;I envelope to health and digital technologies, while Global Health EDCTP3 plans up to €147 million across six research topics relevant to infectious‑disease‑linked digital and clinical innovation.​ MedTech regulation and market structure New guidance and draft implementing regulations around MDR/IVDR and Notified Body conformity assessments are progressing, with consultation timelines running into mid‑January and pointing to tighter but more predictable oversight for EU devices and IVDs.​ EUDAMED’s staged roll‑out, with four modules now functional, starts a six‑month transition that will increase transparency on device registrations, vigilance and market actors from mid‑2026, directly affecting payer scrutiny and MedTech due diligence.​ Market outlook pieces frame 2026 as a “Great Rationalisation” year in European HealthTech/MedTech, with PE‑backed roll‑ups in services and strategic consolidation in AI radiology, digital pathology and tech‑enabled home care, alongside portfolio pruning under MDR/IVDR.​ Startups, AI automation and CES health tech A feature on European startups highlights strong investor interest in AI tools that automate healthcare administration and back‑office workflows, especially those integrating with hospital information systems rather than purely consumer apps.​ Health tech launches at CES 2026 include novel consumer‑adjacent devices such as smart menstrual pads, allergy devices and LED‑based masks, underscoring ongoing convergence between consumer wellness and regulated HealthTech.​ Eindhoven‑based ShanX Medtech secured a €24 million round to accelerate ultra‑rapid diagnostics against antimicrobial resistance, reinforcing the region’s position as a MedTech innovation hub.​ Key implications for deals EU‑backed grants and Horizon Europe calls are providing non‑dilutive capital for cross‑border platforms built around EHDS‑style data flows, which may emerge as future roll‑up nuclei in digital health infrastructure.​ The combination of AI‑focused regulation, EUDAMED transparency and MDR/IVDR simplification is expected to concentrate M&amp;A on fewer, higher‑value assets with clear regulatory narratives and data advantages, particularly in robotics, neuro, advanced diagnostics and AI‑enhanced workflows.&gt;&gt;&gt;European MedTech this week is being shaped by tightening but clearer EU regulation (MDR/IVDR plus EUDAMED timing), notable funding rounds in cardiology and anti‑microbial resistance, and continued investor focus on robotics, neuro and data‑rich devices.​Regulation and guidance The European Commission’s late‑2025 proposal to simplify MDR/IVDR is setting the 2026 agenda, focusing on digitalised procedures, harmonised Notified Body practice and clearer rules for software, AI and nano‑materials.​ EUDAMED has been confirmed as fully mandatory from 28 May 2026, with four modules (actor registration, UDI/device registration, notified bodies &amp; certificates, market surveillance) triggering fixed deadlines and making transparency, traceability and post‑market oversight central to EU MedTech.​ MDCG‑endorsed documents from December 2025 are adding detailed guidance on MDR/IVDR application to software and AI‑driven products, which many MedTech software and SaMD vendors are now using to plan 2026 submissions.​ Market structure and MDR pressure2026 is framed as a defining MDR year, with looming transition deadlines (2027–2028) and Notified Body bottlenecks forcing portfolio rationalisation and prioritisation of higher‑value devices.​ EUDAMED’s go‑live in May 2026 means all devices must be registered in the database before being placed on the EU market, adding operational burden but also standardising data for payers and regulators.​ Strategy and law‑firm notes expect M&amp;A to concentrate on fewer, higher‑quality assets that combine clean MDR roadmaps, strong clinical and economic evidence, and clear health‑technology‑assessment narratives.​ Funding rounds and capital flows French MedTech FineHeart has secured about €83 million in a mix of private capital and non‑dilutive European public funding to advance its implantable device for advanced heart failure, underlining investor appetite for high‑acuity cardiovascular hardware‑plus‑data plays.​ Dutch, female‑led ShanX Medtech has raised €24 million to accelerate ultra‑rapid diagnostics against antimicrobial resistance, reinforcing AMR diagnostics as a key EU strategic priority.​ Weekly funding wraps list ShanX and FineHeart among the top European startup deals for 5–9 January 2026, signalling a strong start to the year for MedTech fundraising.​ Innovation focus: robotics, neuro and data Coverage of Paris‑based Robeauté’s microrobotics platform for diagnosing, treating and monitoring brain disease highlights the tilt toward complex neuro and micro‑robotic interventions as a 2026 MedTech theme.​ Outlook pieces emphasise devices that pair novel hardware with rich data exhaust and AI‑enhanced workflows, especially in cardiovascular, neurovascular, advanced diagnostics and surgical robotics.​ Analysts expect European investors to favour platforms that can integrate with EHDS‑style data infrastructures, creating defensible positions around longitudinal data and decision‑support rather than “device‑only” propositions.​ Key implications for strategy and deals Regulatory clarity around MDR/IVDR and EUDAMED is raising the bar on quality systems and data, increasing the relative value of assets with scalable compliance infrastructure and experienced regulatory teams.​ Portfolio pruning under MDR/IVDR, combined with capital flowing into high‑complexity segments like heart failure, AMR diagnostics and neuro‑robotics, is likely to create a two‑speed market: consolidation among premium, evidence‑rich platforms and potential distress among subscale, non‑differentiated device players.To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener">lloyd@nelsonadvisors.co.uk</a>

Nelson Advisors

Blog

Goldman Sachs, Morgan Stanley and JP Morgan’s combined He...

What is the mood music at JP Morgan Healthcare conference...

The Future of ChatGPT Health

Anthropic launches Claude for Healthcare

Distressed M&A predicted to play a major role in European...

This Week in European HealthTech and MedTech: 9th January...